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the low penetration of kV x-rays limits their useful depth 
range. An interesting solution is to bring the x-ray tube close 
to GNP-loaded tumors. But this can result in non-uniform 
tumor dose distributions. Although a sharp dose falloff is 
useful in brachytherapy, it may not be desirable for thick 
tumors. Here, DE was investigated with the additional aim of 
creating tumor dose uniformity, the idea being that using 
different concentrations of GNP within the tumor can be 
potentially useful as a means of compensating dose falloff.  
Materials and Methods: A miniature intraoperative/ 
brachytherapy x-ray tube with 40-50 kVp photon spectra was 
simulated using MCNP. The tube was simulated in a water 
phantom to obtain its AAPM TG-43 parameters and the model 
was validated against the results of other investigators. The 
tube was first simulated underneath a virtually segmented 
tissue with and without the gold GNP. Then, a 1 cm thick 
tumor was further subdivided into layers to calculate the 
dose distribution. Next, layers of different thicknesses at 
various distances from the tube and also different 
concentrations of GNP were simulated. Then, DE curves were 
plotted for different densities of GNP, namely, 7, 15, and 30 
mg/ml. To allow the use of MCNP for these simulations, the 
GNPs were assumed to be uniformly distributed and also 
sufficiently small to make electron absorption in them 
negligible. Finally, to obtain better DE and dose homogeneity 
concomitantly, the distribution of GNP concentrations (in the 
range 7-30 mg/ml) of the layers were increased progressively 
with depth in tumor by adopting different models, namely, in 
linear (model 1), quadratic (model 2), and exponential 
(model 3) fashions, and their effects were investigated 
separately. 
Results: Although increasing the concentration of GNP 
uniformly within the tumor produced DE at low depths, it 
caused further inhomogeneity due to the additional 
attenuation because of the higher atomic number of the GNP. 
However, increasing the GNP concentration progressively 
with depth in the tumor produced a better homogeneity 
index as well as mean DE. Mean DEs, relative to the case of 
no GNP, for the progressive models 3, 2 and 1 and the 
uniform GNP (7 mg/ml) distribution model were found to be 
50%, 51%, 48%, and 26%, respectively. Also, model 3 offered 
the best homogeneity index. 
Conclusions: Under these conditions, progressive addition of 
GNP with depth in tumor can potentially improve both mean 
DE and dose homogeneity, while the amount of the 
improvement is somewhat dependent on the model of 
concentration increase. Having shown this potential 
improvement, further studies are required to test the 
practical feasibility and implementation of this idea. 
   
PO-1000   
First year of clinical experience with the new generation 
of Gantry for active scanning proton therapy 
F. Albertini1, A. Bolsi1, O. Actis1, M. De Prado1, F. Emert1, A. 
Fredh1, F. Gagnon-Moisan1, C. Goma1, J. Hrbaceck1, S. König1, 
L. Lederer1, A. Lehde1, R. Malyapa1, L. Mikroutsikos1, D. 
Meer1, D. Oxley1, L. Placidi1, S. Safai1, D. Scandurra1, R. 
Schneider1, P. Thoma1, P. Trnkova1, R. Van der Meer1, A.J. 
Lomax1, D.C. Weber1 
1Paul Scherrer Institute (PSI), Center for Proton Therapy, 
Villigen PSI, Switzerland  
 
Purpose/Objective: In November 2014, Gantry-2 (G2) started 
to be used clinically. This second generation gantry is an iso-
centric, compact Gantry with a diameter of only 7.5m and 
with fast 3D scanning with changes in the proton range of 
5mm in water being achieved within 80ms and the dose being 
delivered using narrow pencil beams (3-5 mm) down to 
energies of 70MeV. We report here on our initial experiences 
of this gantry after 1 year of operation. 
Materials and Methods: From November 2013 to November 
2014, 18 patients have been treated with G2, with a 
combination of Single Field Uniform Dose (SFUD) and 
Intensity Modulated Proton Therapy (IMPT). Absolute dose, 
beam range and the spot position have been measured for 
various combinations of beam energies and gantry angles as 
part of the daily QA check procedure. Absolute dose is 
measured in the centre of a 6×6×6 cm3 box using an 
ionization chamber positioned within a PMMA phantom. 
Depth doses are measured using a multilayer Ionization 
Chamber (MLIC), with the position and dimension of the 
delivered spots being verified with ministrip chambers 
embedded in the daily QA phantom.  Patient specific dose 
verifications are performed with a commercial PTW 2D array 
seven2.9 for every field before being applied to the patient 
and have been analyzed using the gamma (3%/3 mm) 
evaluation. Additionally, delivered dose distributions have 
been reconstructed in the patient geometries using a 
machine-log-file driven independent dose calculation. 
Results: Figure 1 shows an example of the plan and DVHs for 
the first patient treated at G2.  In total, 37 treatment series 
have been applied. The number of fields per plan ranged 
from 3 to 4 (mean, 3.1). PTV volumes are in the range 20-220 
ml. The current delivery rate of about 3000 spots per minute 
translates into a median treatment time per individual field 
of 37s (mean of 1 minute and 49s and standard deviation of 
59s). Results of the daily QA checks of absolute dose and 
beam range are excellent with measured doses and ranges 
differing from the expected values by < 0.2% and by <0.1 mm 
respectively.  Patient specific field verifications show a very 
good agreement between measurement and calculation with 
more than 98% of points over all fields passing the gamma 
criteria. Finally, maximum single point differences of <2.5% 
have been found between the planned and the reconstructed 
delivered doses calculated from the log-files over all series.  
 
 
Conclusions: The introduction of G2 into clinical routine has 
been smooth and has resulted in excellent reproducibility and 
delivery accuracy. Although we have deliberately started 
with a cautious approach in terms of patient load and target 
location, our current experience clearly indicates the scope 
for increased patient throughput and expanded indications in 
the near future. 
